ArticleJournal of medical biochemistry2025
Diagnostic value and clinical significance of Ki-67, PI3K, and Fascin in patients with oral squamous cell carcinoma.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) is a common and aggressive malignancy that poses significant challenges in terms of diagnosis and prognosis. Identifying reliable biomarkers for early detection and prognostication is essential for improving patient outcomes. Ki-67, PI3K, and Fascin are potential biomarkers involved in OSCC progression, but their combined diagnostic value and clinical significance remain underexplored. Objective: This study aims to evaluate the expression levels of Ki-67, PI3K, and Fascin in OSCC tissues and investigate their associations with clinical and pathological parameters, including tumour differentiation, cervical lymph node metastasis, and TNM staging. Methods: A retrospective analysis was conducted on 35 patients diagnosed with OSCC, with tumour tissues subjected to immunohistochemical staining to assess the expression of Ki-67, PI3K, and Fascin. The association between marker expression and clinical features was evaluated, and correlations between the markers were analysed. Results: The expression levels of Ki-67, PI3K, and Fascin were significantly higher in OSCC tissues compared to paracancerous tissues (P< 0.05). Higher expression levels of these markers were associated with well-differentiated tumours and cervical lymph node metastasis (P< 0.05). However, no significant differences were found between early and advanced tumour stages (P> 0.05). Strong positive correlations were observed between Ki-67, PI3K, and Fascin expression, indicating potential shared molecular pathways involved in OSCC progression. Conclusions: Ki-67, PI3K, and Fascin are promising biomarkers for diagnosing and predicting the prognosis of OSCC. Their combined assessment could aid in early detection, identification of high-risk patients, and determination of appropriate treatment strategies. Further research is needed to fully understand the molecular mechanisms underlying their role in OSCC progression and to assess their clinical utility in patient management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.